IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i18p11437-d912348.html
   My bibliography  Save this article

Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases

Author

Listed:
  • Iwona Smarz-Widelska

    (Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland)

  • Małgorzata Syroka-Główka

    (Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland)

  • Joanna Janowska-Jaremek

    (Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland)

  • Małgorzata M. Kozioł

    (Chair and Department of Medical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland)

  • Wojciech Załuska

    (Department of Nephrology, Medical University of Lublin, 20-954 Lublin, Poland)

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation. Immune activation by viruses, including SARS-CoV-2, can lead to the development of an episode of aHUS against a background of genetic dysregulation in the complement pathway. This paper presents an analysis of two cases of aHUS—siblings diagnosed with familial disease, with a genetic predisposition to aHUS, in whom infection with SARS-CoV-2 was a strong trigger of disease recurrence. The quick recognition and treatment with eculizumab in the early stage of the disease resulted in a rapid improvement in clinical conditions and laboratory parameters.

Suggested Citation

  • Iwona Smarz-Widelska & Małgorzata Syroka-Główka & Joanna Janowska-Jaremek & Małgorzata M. Kozioł & Wojciech Załuska, 2022. "Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases," IJERPH, MDPI, vol. 19(18), pages 1-6, September.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:18:p:11437-:d:912348
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/18/11437/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/18/11437/
    Download Restriction: no
    ---><---

    More about this item

    Keywords

    aHUS; TMA; eculizumab; COVID-19;
    All these keywords.

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:18:p:11437-:d:912348. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.